Table 1 Clinical characteristics and biochemical data of patients with impaired kidney function stratified into two groups based on cardiac function
Characteristics of total subjects | p value | |||
|---|---|---|---|---|
|  | Mean (±SD), n (%) |  | ||
| Â | Overall | Without SHF | With SHF | Â |
|  | n = 190 | n = 95 | n = 95 |  |
Age (years) | 58 ± 15 | 53 ± 15 | 63 ± 14 | 0.00 |
Male gender (%) | 128 (67.4) | 59 (62.1) | 69 (72.6) | 0.12 |
BMI (kg/m 2 ) | 23 ± 3.1 | 24.1 ± 3.2 | 21.9 ± 2.5 | 0.00 |
Hypertension (%) | 141 (74.6) | 71 (74.7) | 70 (73.7) | 0.77 |
Anemia (%) | 129 (67.9) | 64 (67.4) | 65 (68.4) | 0.87 |
Diabetes (%) | 108 (56.8) | 49 (51.6) | 59 (62.1) | 0.14 |
Dyslipidemia (%) | 69 (36.3) | 33 (34.7) | 36 (37.9) | 0.65 |
Ischemic heart disease (%) | 39 (20.5) | 0 | 39 (41.1) | 0.00 |
Smoking history (%) | 6 (3.2) | 1 (1.1) | 5 (5.3) | 0.09 |
Cerebrovascular accident (%) | 4 (2.1) | 1 (1.1) | 3 (3.2) | 0.31 |
Malignancy (%) | 1 (0.5) | 0 | 1 (1.1) | 0.31 |
Alcohol intake (%) | 1 (0.5) | 1 (1.1) | 0 | 0.31 |
ACE inhibitors | 91 (47.9) | 51 (53.7) | 40 (42.1) | 0.11 |
Statins | 69 (36.3) | 33 (34.7) | 36 (37.9) | 0.65 |
Calcium channel blockers | 49 (25.8) | 32 (33.7) | 17 (17.9) | 0.01 |
Diuretics | 41 (21.6) | 19 (20) | 22 (23.2) | 0.59 |
Digoxin | 22 (11.6) | 0 | 22 (23.2) | 0.00 |
ARB | 20 (10.5) | 8 (8.4) | 12 (12.6) | 0.34 |
Beta blocker | 13 (6.8) | 12 (12.6) | 1 (1.1) | 0.00 |
Stage 3 CKD (%) | 77 (40.5) | 41 (43.2) | 36 (37.9) | 0.75 |
Stage 4 CKD (%) | 77 (40.5) | 37 (38.9) | 40 (42.1) | 0.75 |
Stage 5 CKD (%) | 36 (18.9) | 17 (17.9) | 19 (20) | 0.49 |
Ejection fraction (%) | 42.9 ± 6.8 | 59.3 ± 3.5 | 26.6 ±10.2 | 0.00 |
eGFR (ml/min) | 27.7 ± 14 | 29.1 ± 15.1 | 26.2 ± 12.9 | 0.15 |
Cr (mg/dl) | 3.2 ± 2.2 | 3.3 ± 2.4 | 3.0 ± 1.8 | 0.34 |
Log BNP (pg/ml) | 2.2 ± 0.5 | 2.0 ± 0.4 | 2.4 ± 0.6 | 0.00 |
Log NT-proBNP (pg/ml) | 3.4 ± 0.6 | 2.9 ± 0.6 | 3.9 ± 0.6* | 0.00 |